2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3508 A genetically engineered mouse model of B-cell specific Notch2 activation alone or in combination with Klf2 inactivation recapitulates human splenic marginal zone lymphoma.

Federico Jauk, MD, Deborah Piffaretti, PhD2, Adalgisa Condoluci, MD, PhD3, Lodovico Terzi Di Bergamo4, Matin Salehi, PhD5, Gabriela Forestieri6, Consuelo Bertossi7, Martin Richard Faderl, PhD, MSc, BSc8, Roberto Accogli9, Alexandra Valera10, Francesca Molinari11, Tess Brodie12, Evelina Rogges13, Simone Mosole14, Reiner Siebert, MD15, Alexandar Tzankov16, Davide Rossi I, MD, PhD17
1 Clinic of Pathology, IDISI, Ente Ospedaliero Cantonale, Locarno, Switzerland, Laboratory of Experimental Hematology, Institute of Oncology Research (IOR), Bellinzona, Switzerland
2 Laboratory of Experimental Hematology, Institute of Oncology Research (IOR), Bellinzona, Switzerland
3 Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
4 Laboratory of Experimental Hematology, Institute of Oncology Research (IOR), Bellinzona, Switzerland
5 Laboratory of Experimental Hematology, Institute of Oncology Research (IOR), Bellinzona, Switzerland
6 Laboratory of Experimental Hematology, Institute of Oncology Research (IOR), Bellinzona, Switzerland
7 Laboratory of Experimental Hematology, Institute of Oncology Research (IOR), Bellinzona, Switzerland
8 Laboratory of Experimental Hematology, Institute of Oncology Research (IOR), Bellinzona, Switzerland
9 Clinic of Pathology, IDISI, Ente Ospedaliero Cantonale, Locarno, Switzerland
10 Clinic of Pathology, IDISI, Ente Ospedaliero Cantonale, Locarno, Switzerland
11 Clinic of Pathology, IDISI, Ente Ospedaliero Cantonale, Locarno, Switzerland
12 Experimental Pathology Facility, Institute of Oncology Research, Bellinzona, Switzerland
13 Department of Medical and Surgical Sciences and Translational Medicine, PhD School in Translational Medicine and Oncology, Sapienza University of Rome, Rome, Italy
14 Experimental Pathology Facility, Institute of Oncology Research, Bellinzona, Switzerland
15 Institute of Human Genetics, Ulm University Hospital, Ulm, Germany
16 Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
17 Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland, Laboratory of Experimental Hematology, Institute of Oncology Research (IOR), Bellinzona, Switzerland

Introduction: Splenic marginal zone lymphoma (SMZL) is an indolent B-cell neoplasm characterized by mutations that stabilize the NOTCH2 protein in its active form (25% of cases) and by inactivating mutations and/or deletions of KLF2 (25% of cases). NOTCH2 and KLF2 genetic lesions co-occur in a substantial fraction of SMZL cases (10%). Collectively, mutations affecting NOTCH2 and/or KLF2 account for approximately 40% of SMZL cases. Although this represents the most common genetic configuration in SMZL, the contribution of these lesions to SMZL lymphomagenesis remains unproven.
Aims: To determine whether B-cell-specific Notch2 activation and/or Klf2 inactivation induce lymphomagenesis in genetically engineered mouse models, and to assess the morphological, immunophenotypic, and molecular resemblance of the resulting mouse lymphomas to human SMZL.
Methods: C57BL/6 mice carrying Cd19-Cre were crossed with mice carrying floxed Notch2 gain-of-function (intracellular Notch2 domain) and/or floxed Klf2 knockout alleles, generating the following cohorts: Cd19-Cre (Control, n=38), Cd19-Cre/Notch2fl/+ (N2, n=43), Cd19-Cre/Klf2fl/+ (K2het, n=24), Cd19-Cre/Klf2fl/fl (K2hom, n=29), Cd19-Cre/Notch2fl/+/Klf2fl/+ (N2/K2het, n=26), and Cd19-Cre/Notch2fl/+/Klf2fl/fl (N2/K2hom, n=25). Since the exact cell of origin of SMZL along the B-cell differentiation continuum remains unknown, Cre-mediated recombination was confined to the B-cell compartment. Age/sex-matched mice underwent chronic immunization with sheep red blood cells and were monitored for over 100 weeks. Spleen, liver, bone marrow and inguinal lymph node were collected for paraffin inclusion and single cell suspensions. Lymphoma assessment was based on morphology and NGS-based clonality. Immunohistochemistry, multiplexed immunofluorescence (MACSima) and FISH assays for Bcl6 and Myc genes were performed on FFPE tissue of lymphoma samples.
Results: Lymphoma penetrance was 16% in Controls, 8% in K2het, 3% in K2hom, 58% in N2, 58% in N2/K2het in 52% for N2/K2hom genotypes. Compared to Controls, lymphoma risk was significantly increased in N2 (RR 3.7, p<0.001), N2/K2het (RR 3.7, p<0.001) and N2/K2hom (RR 3.3, p=0.004), but not in K2het or K2hom. N2, N2/K2het and N2/K2hom mice showed a shorter overall survival compared to controls (p<0.001). Overall, 43 SMZL (K2het n=2, K2hom=1, N2 n=19, N2/K2het n=13, N2/K2hom n=8) and 13 DLBCL (N2 n=6, N2/K2het n=2, N2/K2hom n=5) were developed within the experimental genotypes. Lymphomas involved spleen in all cases and presented with splenomegaly (p<0.001 vs. Controls).
SMZL cases were defined as small-cell lymphoid proliferations with enlarged marginal zone, infiltrating the white pulp and extending to the red pulp. The cell type was predominantly monocytoid (48.5%) or mixed (42%) over predominantly centrocytoid (9%). Phenotypically they expressed Pax5 (100%), B220 (81%), Irf4 (69%) and IgM (81%), but not Cd5 (0%), Bcl6 (0%), Cd138 (0%) or IgG (0%). Median Ki67 expression was 15% (range: 10-40%). The liver was involved in 22% of cases, while inguinal lymph node involvement was infrequent (11%). Notch2 and Klf2 double-mutant genotypes (N2/K2het plus N2/K2hom) SMZLs showed increased number of large cells compared to N2 genotype (FDR<0.01).
DLBCL cases were defined as the presence of sheets of large cells disrupting the splenic architecture. The predominant cell type was centroblastic (64%) over immuno-/plasmablastic (36%). Phenotypically they expressed Pax5 (100%), B220 (90%), Irf4 (72.7%), IgM (81%), but not Cd5 (0%), Bcl6 (9%), Cd138+ (9%), or IgG (0%). Median Ki67 expression was 80% (range: 50-80%). All DLBCL tested negative for Bcl6 or Myc rearrangements. Most cases had liver (72%) and inguinal lymph node (85.7%) involvement.
From an immunogenetic standpoint, SMZL and DLBCL IGHV gene usage was biased in 64% of productive rearrangements compared with the normal B-cell repertoire of age-matched immunized and non-immunized mouse spleen controls (FDR<0.001). Stereotypy of the HCDR3 was detected in 15% of cases accounting for 5 distinct clusters.
Conclusion: B-cell-specific Notch2 activation, either alone or in combination with Klf2 inactivation, drives lymphoma development with high penetrance. Lymphomas in our mouse model recapitulate the key morphological and immunophenotypic features of human SMZL, including progression to DLBCL. Biased IGHV gene usage and stereotyped HCDR3 sequences support a role for antigen-driven selection in disease pathogenesis.

Federico Jauk, MD: No relevant conflicts of interest to declare.